5 mins | 30 mins | Hourly | Daily | Weekly |
---|---|---|---|---|
BUY | BUY | BUY | SELL | SELL |
5 mins | 30 mins | Hourly | Daily | Weekly | |
---|---|---|---|---|---|
MA5 | 2.07▼ | 2.07▼ | 2.05▲ | 2.06▲ | 2.14▼ |
MA10 | 2.05▲ | 2.04▲ | 2.02▲ | 1.97▲ | 2.25▼ |
MA20 | 2.03▲ | 2.02▲ | 1.99▲ | 2.11▼ | 2.53▼ |
MA50 | 2.00▲ | 2.06▼ | 2.14▼ | 2.24▼ | 3.49▼ |
MA100 | 2.08▼ | 2.20▼ | 2.22▼ | 2.58▼ | 6.52▼ |
MA200 | 2.20▼ | 2.26▼ | 2.29▼ | 3.32▼ | 11.05▼ |
5 mins | 30 mins | Hourly | Daily | Weekly | |
---|---|---|---|---|---|
MACD | 0.007▲ | 0.014▲ | 0.019▲ | 0.012▲ | 0.054▲ |
RSI | 54.918▲ | 51.932▲ | 50.560▲ | 48.564▼ | 37.535▼ |
STOCH | 88.443▲ | 82.324▲ | 70.398 | 61.251 | 35.696 |
WILL %R | -33.333 | -33.333 | -24.010▲ | -29.412 | -76.136▼ |
CCI | 61.957 | 74.229 | 59.965 | 31.270 | -133.375▼ |
Monday, April 14, 2025 09:38 AM
SNGX READ THE FULL SNGX RESEARCH REPORT Business Update Interim Data from IIS Study Shows 75% Response Rate and Three Complete Responses On April 14, 2025, Soligenix, Inc. (NASDAQ:SNGX) announced ...
|
Monday, April 14, 2025 05:35 AM
(RTTNews) - Soligenix, Inc. (SNGX), a late-stage biopharmaceutical ... of the author and do not necessarily reflect those of Nasdaq, Inc. Founded in the late 1990s by Andrew Mariathasan in New ...
|
Sunday, April 13, 2025 10:38 PM
On April 14, 2025, Soligenix, Inc. (NASDAQ:SNGX) announced interim data from the ongoing, open label, investigator-initiated study (IIS) of HyBryte™ (synthetic hypericin) treatment for up to 54 ...
|
date | open | high | low | close | volume |
---|---|---|---|---|---|
17/04/25 | 2.11 | 2.11 | 2.00 | 2.10 | 30,763 |
16/04/25 | 2.08 | 2.11 | 1.9583 | 2.06 | 112,038 |
15/04/25 | 1.89 | 2.07 | 1.8701 | 2.00 | 111,766 |
14/04/25 | 2.02 | 2.13 | 1.85 | 1.96 | 3,231,728 |
11/04/25 | 1.96 | 2.23 | 1.955 | 2.175 | 49,839 |
10/04/25 | 1.95 | 1.95 | 1.86 | 1.89 | 27,238 |
09/04/25 | 1.7699 | 1.9601 | 1.7699 | 1.95 | 34,453 |
08/04/25 | 1.89 | 1.945 | 1.83 | 1.83 | 21,425 |
07/04/25 | 1.84 | 1.89 | 1.78 | 1.87 | 30,253 |
04/04/25 | 2.07 | 2.08 | 1.68 | 1.84 | 53,214 |
|
|
||||
|
|
||||
|
|